The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 27, 2017

Filed:

Mar. 02, 2012
Applicants:

Judy Lieberman, Brookline, MA (US);

Fabio Petrocca, Boston, MA (US);

Inventors:

Judy Lieberman, Brookline, MA (US);

Fabio Petrocca, Boston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/574 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/713 (2006.01); A61K 38/05 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/713 (2013.01); A61K 38/05 (2013.01); G01N 33/57415 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/10 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract

Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.


Find Patent Forward Citations

Loading…